Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular DystrophyGlobeNewsWire • Wednesday
Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should KnowZacks Investment Research • 04/10/24
How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%Zacks Investment Research • 03/25/24
Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 03/07/24
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceGlobeNewsWire • 03/06/24
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/29/24
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular DystrophyGlobeNewsWire • 02/27/24
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29GlobeNewsWire • 02/22/24
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward CommercializationGlobeNewsWire • 02/20/24
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2GlobeNewsWire • 01/24/24
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility AnalysisGlobeNewsWire • 12/11/23
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/14/23
Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14GlobeNewsWire • 11/07/23
Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to DeclineZacks Investment Research • 11/02/23
Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular DystrophySeeking Alpha • 10/25/23
After Plunging -52.01% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)Zacks Investment Research • 10/25/23
After Plunging -50.99% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)Zacks Investment Research • 10/24/23
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 ProgramGlobeNewsWire • 10/19/23
Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle SocietyGlobeNewsWire • 10/10/23
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular DystrophyGlobeNewsWire • 09/29/23